BNR vs EXAS vs GH vs NTRA vs ACMR

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -4. 0% for Burning Rock Biotech Limited (BNR). ACM Research, Inc. (ACMR) offers the better valuation at 43. 2x trailing P/E (29. 7x forward), making it the more compelling value choice. Analysts rate Burning Rock Biotech Limited (BNR) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, ACM Research, Inc.

is actually cheaper at 29. 7x.

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +133. 4%, compared to -93. 9% for Burning Rock Biotech Limited (BNR). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus BNR's -93. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus ACM Research, Inc. 's 3. 24β — meaning ACMR is approximately 2585% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Burning Rock Biotech Limited (BNR) carries a lower debt/equity ratio of 9% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus -4. 0% for Burning Rock Biotech Limited (BNR). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -10. 5% for ACM Research, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACM Research, Inc.

(ACMR) is the more profitable company, earning 10. 4% net margin versus -67. 2% for Burning Rock Biotech Limited — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACMR leads at 12. 1% versus -69. 3% for BNR. At the gross margin level — before operating expenses — BNR leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACM Research, Inc.

(ACMR) trades at 29. 7x forward P/E versus 582. 8x for Exact Sciences Corporation — 553. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GH: 44. 3% to $133. 14.

In this comparison, ACMR (0.

2% yield) pays a dividend. BNR, EXAS, GH, NTRA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). ACM Research, Inc. (ACMR) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, ACMR: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BNR (Healthcare) and EXAS (Healthcare) and GH (Healthcare) and NTRA (Healthcare) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BNR is a small-cap quality compounder stock; EXAS is a mid-cap high-growth stock; GH is a mid-cap high-growth stock; NTRA is a mid-cap high-growth stock; ACMR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.